223472-25-1

Upstream product

• 119109-58-9 4-(S)-[4-(N-benzyloxycarbonylamino)-5-hydroxy]pentanoic acid methyl ester 
• 911050-88-9 methyl (2S,4S)-4-[(benzyloxy)carbonyl]amino-5-ethoxymethoxy-2-methylpentanoate 
• 223472-23-9 methyl (4S)-4-{[(benzyloxy)carbonyl]amino}-5-(ethoxymethoxy)pentanoate 
• 911050-90-3 methyl (2S,4S)-5-ethoxymethoxy-2-methyl-4-[(4-phenoxybenzoyl)amino]pentanoate 

Relevant academic research and scientific papers

Design and synthesis of an orally active matrix metalloproteinase inhibitor

A series of 4-(4-phenoxy)benzoylamino-4-methoxymethyloxymethyl butyric acid hydroxamates, which were derived from l-glutamic acid, were synthesized and evaluated as matrix metalloproteinase inhibitors. Most of the compounds listed in Tables 1-3 exhibited

Aminobutyric acid derivatives

An aminobutyric acid derivative of the formula (I): (wherein all symbols are as defined in the specification) and salt thereof. salt thereof. The compounds of the formula (I) possess an inhibitory activity on matrix metalloproteinase and are useful for prevention and/or treatment of diseases, for example, rheumatoid diseases, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune disease (e.g. Crohn's disease, Sjogren's syndrome), disease caused by vascular emigration or infiltration of leukocytes, arterialization, multiple sclerosis, aorta aneurysm, endometriosis.